Prostate cancer: New answers prompt new questions regarding cell of origin

[1]  G. Risbridger,et al.  Stem cells in prostate cancer: treating the root of the problem. , 2010, Endocrine-related cancer.

[2]  M. Shen,et al.  Molecular genetics of prostate cancer: new prospects for old challenges. , 2010, Genes & development.

[3]  D. Moscatelli,et al.  PINing Down the Origin of Prostate Cancer , 2010, Science Translational Medicine.

[4]  R. T. Divrik,et al.  Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. , 2010, European urology.

[5]  Jiaoti Huang,et al.  Identification of a Cell of Origin for Human Prostate Cancer , 2010, Science.

[6]  S-H Tan,et al.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.

[7]  C. Bieberich,et al.  MYC and Prostate Cancer. , 2010, Genes & cancer.

[8]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[9]  L. Lamb,et al.  E-cadherin-mediated survival of androgen-receptor-expressing secretory prostate epithelial cells derived from a stratified in vitro differentiation model , 2010, Journal of Cell Science.

[10]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[11]  Eran Segal,et al.  Module map of stem cell genes guides creation of epithelial cancer stem cells. , 2008, Cell stem cell.

[12]  H. Ozen,et al.  The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. , 2006, The Journal of urology.

[13]  H. Herr.  Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. , 2005, The Journal of urology.

[14]  M. Grimm,et al.  Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. , 2003, The Journal of urology.

[15]  Michael Cookson,et al.  Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. , 2001, The Journal of urology.

[16]  G. Dalbagni,et al.  Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? , 2007, The Journal of urology.